Evolution of cancer pharmacological treatments at the turn of the third millennium
The medical history of cancer began millennia ago. Historical findings of patients with
cancer date back to ancient Egyptian and Greek civilizations, where this disease was …
cancer date back to ancient Egyptian and Greek civilizations, where this disease was …
Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience
G Salles, M Barrett, R Foà, J Maurer, S O'Brien… - Advances in …, 2017 - Springer
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
Strategies in the design of nanoparticles for therapeutic applications
RA Petros, JM DeSimone - Nature reviews Drug discovery, 2010 - nature.com
Engineered nanoparticles have the potential to revolutionize the diagnosis and treatment of
many diseases; for example, by allowing the targeted delivery of a drug to particular subsets …
many diseases; for example, by allowing the targeted delivery of a drug to particular subsets …
Assessment of the evolution of cancer treatment therapies
Cancer therapy has been characterized throughout history by ups and downs, not only due
to the ineffectiveness of treatments and side effects, but also by hope and the reality of …
to the ineffectiveness of treatments and side effects, but also by hope and the reality of …
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
DG Maloney, AJ Grillo-López, CA White… - Blood, The Journal …, 1997 - ashpublications.org
Abstract IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell–
specific antigen CD20 expressed on non-Hodgkin's lymphomas (NHL). The MoAb mediates …
specific antigen CD20 expressed on non-Hodgkin's lymphomas (NHL). The MoAb mediates …
Monoclonal antibody therapy of cancer
GP Adams, LM Weiner - Nature biotechnology, 2005 - nature.com
The most significant recent advances in the application of monoclonal antibodies (mAbs) to
oncology have been the introduction and approval of bevacizumab (Avastin), an anti …
oncology have been the introduction and approval of bevacizumab (Avastin), an anti …
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
FJ Hsu, C Benike, F Fagnoni, TM Liles, D Czerwinski… - Nature medicine, 1996 - nature.com
In this pilot study, we investigated the ability of autologous dendritic cells pulsed ex vivo with
tumor–specific idiotype protein to stimulate host antitumor immunity when infused as a …
tumor–specific idiotype protein to stimulate host antitumor immunity when infused as a …
[图书][B] Controlled drug delivery: fundamentals and applications
J Robinson, VHL Lee - 1987 - api.taylorfrancis.com
Controlled Drug Delivery Page 1 Controlled Drug Delivery Page 2 DRUGS AND THE
PHARMACEUTICAL SCIENCES A Series of Textbooks and Monographs Edited by James …
PHARMACEUTICAL SCIENCES A Series of Textbooks and Monographs Edited by James …
Immunotherapy: past, present and future
TA Waldmann - Nature medicine, 2003 - nature.com
Harnessing the immune system to treat chronic infectious diseases or cancer is a major goal
of immunotherapy. Among others, impediments to this aim include host failure to identify …
of immunotherapy. Among others, impediments to this aim include host failure to identify …
A tale of two antibodies: obinutuzumab versus rituximab
CL Freeman, LH Sehn - British journal of haematology, 2018 - Wiley Online Library
While rituximab has dramatically improved outcomes for patients with CD20+ malignancies
for two decades, responses are not universal and resistance can develop. Obinutuzumab …
for two decades, responses are not universal and resistance can develop. Obinutuzumab …